The importance of assessing behaviour and cognition in antiepileptic drug trials in children and adolescents
Author:
- 20 December 2016
- journal article
- review article
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 117 (2) , 425-432
Abstract
It has long been recognised that uncontrolled childhood epilepsy is detrimental to cognition and behaviour, impacting on a patient’s ability to succeed academically. Patients who experience more frequent and serious seizures are at greater risk for cognitive decline, emphasising the need for more effective epilepsy treatments to bring seizures under control. That said, although more effective antiepileptic drugs (AEDs) have the potential to limit the impact of uncontrolled seizures on cognitive and behavioural function, recently it has been acknowledged that deficits in these functions may be caused by AEDs themselves. The cognitive and behavioural effects of older-generation AEDs have been determined largely from AE reporting rather than from specific assessment. Recently, clinical trials of newer-generation AEDs, such as topiramate, levetiracetam and perampanel, have included standardised neuropsychological tests as outcome measures to assess their impact on cognition and behaviour in children and adolescents. However, to understand how we may limit the cognitive and behavioural side effects of AEDs, it is necessary for us to gain a fuller, more accurate, characterisation of their true impact. Such insight will depend on sophisticated and standardised approaches to the design of AED clinical trials. This review provides a general overview of our current understanding of the impact of both epilepsy and AEDs on cognition and behaviour, before focusing on the AEDs for which more detailed assessment, using standardised cognitive and behavioural measures, has been undertaken. We will then go on to discuss the key elements in the design of future AED clinical trials to address current unmet needs.Keywords
Funding Information
- Eisai
This publication has 54 references indexed in Scilit:
- A Long-Term Open-Label Extension Study Assessing Cognition and Behavior, Tolerability, Safety, and Efficacy of Adjunctive Levetiracetam in Children Aged 4 to 16 Years With Partial-Onset SeizuresJournal of Child Neurology, 2011
- New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Therapeutic Advances in Drug Safety, 2011
- Neurocognitive effects of adjunctive levetiracetam in children with partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, noninferiority trialEpilepsia, 2009
- Cognitive Side Effects of Valproic Acid-Induced Hyperammonemia in Children With EpilepsyJournal of Clinical Psychopharmacology, 2007
- Epilepsy and CognitionEpilepsy Currents, 2007
- Efficacy and Safety of Zonisamide Monotherapy in a Cohort of Children With EpilepsyPediatric Neurology, 2006
- Chronic epilepsy and cognition: A longitudinal study in temporal lobe epilepsyAnnals of Neurology, 2003
- NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodilCognitive Brain Research, 1992
- Phenobarbital for Febrile Seizures — Effects on Intelligence and on Seizure RecurrenceNew England Journal of Medicine, 1990
- Side effects of phenobarbital in toddlers; behavioral and cognitive aspectsThe Journal of Pediatrics, 1979